IDT Biologika, a Dessau, Germany-based manufacturer of vaccines and biopharmaceuticals, has won a contract from the Biomedical Advanced Research and Development Authority (BARDA) within the office of the Assistant for Preparedness and Response at the United States Department of Health and Human Services to provide live virus-filling and finishing services with an initial commitment of $100,000, subject to task order(s), for a maximum amount of $50 million. BARDA seeks to establish fill/finish capabilities for use of live-vectored virus products in clinical development through licensure.

BARDA has contracted with IDT Biologika to provide services to support cGMP and non-GMP filling and finishing of a variety of medical countermeasure products. The company will initially provide services to support live virus/vectored vaccine fill/finish and potentially for small-molecule injectables, large-molecule sterile injectables, monoclonal antibodies, and other development-stage and US Food and Drug Administration-approved medical countermeasures.

The BARDA contract may be performed over a five-year period and addresses two types of requirements: fill/finish services to support the development of live/vectored virus product candidates and medical countermeasures and rapid response readiness for fill/finish services for medical countermeasures within an accelerated time frame.

Source: IDT Biologika